Recent

% | $
Quotes you view appear here for quick access.

Arrayit Corporation Message Board

  • angel5734a angel5734a Mar 5, 2013 11:10 AM Flag

    Avant Diagnostics Test Pipeline

    Ovarian cancer OvaDx® FDA submission: Q4, 2014 Potential revenue: $500M
    VIP Plavix® FDA submission: Q2, 2015 Potential revenue: $990M
    Parkinson’s Disease FDA submission: Q4, 2015 Potential revenue: $500M
    Prostate cancer FDA submission: Q4, 2016 Potential revenue: $1.5B

    We know that they are trying to get a strategic partner to accellerate PDx submission,

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Per today's presentation revision OvaDx submission is Q2 2013, and the rest of the tests are one year earlier. See below updated chart:

      Ovarian cancer OvaDx® FDA submission: Q2, 2013 Potential revenue: $500M
      VIP Plavix® FDA submission: Q2, 2014 Potential revenue: $990M
      Parkinson’s Disease FDA submission: Q4, 2014 Potential revenue: $500M
      Prostate cancer FDA submission: Q4, 2015 Potential revenue: $1.5B

    • What? in the power point presentation it says ovaDX submission Q2 2013, as in now.

 
ARYC
0.00070.0000(0.00%)Aug 26 3:16 PMEDT